Overview An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease Status: Completed Trial end date: 2011-03-01 Target enrollment: Participant gender: Summary The purpose of the study is to determine the drug characteristics of Ticagrelor, and to determine if 4 weeks treatment will reduce the blood clotting. Phase: Phase 2 Details Lead Sponsor: AstraZenecaTreatments: ClopidogrelTicagrelor